Orphan Therapeutics, LLC is aprivately held drug development company. It was founded in 2003 with the purpose to develop and seek regulatory approval for its first product, Lucassin® (terlipressin), for the treatment of Hepatorenal Syndrome (HRS) type 1 in the US, Canada, Japan and Australia. In March 2010, Orphan Therapeutics licensed the New Drug Application (NDA) and its development rights for terlipressin in North America and Australia to Ikaria Inc., which was acquired by Mallinckrodt in April 2015. Orphan Therapeutics has a continued commitment to assist the Mallinckrodt team through the FDA approval process.
December 7, 2015
Mallinckrodt plc Discusses R&D Initiatives, Company Outlook at Investor Briefing
April 16, 2015
Mallinckrodt completes acquisition of Ikaria
April 23, 2012
Lucassin® Approved in Australia
March 30, 2010
IKARIA® Acquires New Drug Application for Lucassin®
Investigational New Drug Application Also Acquired
Copyright 2016 - Orphan Therapeutics. All rights reserved.